EUVIMEDEUVIMED entdecken
Crossref

Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence

BJU International · 2023

DOI: 10.1111/bju.16088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2023. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Kidney Calculi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellProstatic NeoplasmsKidney CalculiMaleHumansImmune Checkpoint InhibitorsHydrochlorothiazide

Substanzen

Immune Checkpoint InhibitorsHydrochlorothiazide

Zitieren

APA

(2023). Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence. BJU International. https://doi.org/10.1111/bju.16088

Vancouver

Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence. BJU International. 2023. doi:10.1111/bju.16088

BibTeX
@article{euvimed2023,
  title = {Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.16088}
}
Kostenlos starten →